To continue reading this article, sign up for FREE to
Membership is FREE
and provides you with
instant access
to email newsletters, digital publications, our full content catalogue & more...
Already have an account?
Celtic Pharma and PolyTherics Announce Investment into Biopharmaceutical Programme
Read time: Less than a minute
Celtic Pharma Holdings Advisors LLP (CPHA), the advisor to Celtic Pharma Holdings II LP (CP2), together with PolyTherics Limited (PolyTherics), announces an investment by Leverton Licence Holdings Limited (LLH), a wholly-owned subsidiary of CP2, into a research programme to develop a novel biopharmaceutical molecule.
This research programme will be undertaken jointly by PolyTherics and Cantab BioPharmaceuticals Limited (Cantab), a wholly-owned subsidiary of CP2 based in Cambridge, UK.
PolyTherics will receive an upfront payment and ongoing technical support for the research, while LLH may elect to submit two further proteins for research under the collaboration.
PolyTherics grants LLH an option to license products arising from the research collaboration, with PolyTherics receiving a share of any commercial returns. Further details of the agreement terms were not disclosed.
Dr Keith Powell, Chief Executive Officer of PolyTherics, said: “We are delighted to establish a working relationship with CP2 and its subsidiaries Cantab and LLH through this new therapeutic programme. Importantly, as we embark as a company on the development of our own bio-better products, we are excited to share in the rewards of product commercialization resulting from this new collaboration”.
This research programme will be undertaken jointly by PolyTherics and Cantab BioPharmaceuticals Limited (Cantab), a wholly-owned subsidiary of CP2 based in Cambridge, UK.
PolyTherics will receive an upfront payment and ongoing technical support for the research, while LLH may elect to submit two further proteins for research under the collaboration.
PolyTherics grants LLH an option to license products arising from the research collaboration, with PolyTherics receiving a share of any commercial returns. Further details of the agreement terms were not disclosed.
Dr Keith Powell, Chief Executive Officer of PolyTherics, said: “We are delighted to establish a working relationship with CP2 and its subsidiaries Cantab and LLH through this new therapeutic programme. Importantly, as we embark as a company on the development of our own bio-better products, we are excited to share in the rewards of product commercialization resulting from this new collaboration”.
Add Technology Networks as a preferred Google source to see more of our trusted coverage.
